Connect with us
Prague Gaming & TECH Summit 2025 (25-26 March)

Fintech PR

A report from People’s Daily: PLA support base in Djibouti pursues peace, cooperation, friendship

Published

on

a-report-from-people’s-daily:-pla-support-base-in-djibouti-pursues-peace,-cooperation,-friendship

Beijing, Sept. 12, 2023 /PRNewswire/ — A ceremony marking the entry of troops into the Chinese People’s Liberation Army (PLA) support base in Djibouti was held at the base’s barracks on August 1, 2017, marking the completion and official operation of the base.

The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.

In accordance with UN Security Council resolutions, China has deployed vessels to the Gulf of Aden and the waters off the Somali coast on escort missions since 2008. During the process, Chinese officers and men encountered difficulties in replenishing food and fuel, and Djibouti offered logistical support in multiple instances.

The construction of the support base enables China to better fulfill its international obligations such as escorts and humanitarian rescue in the Gulf of Aden and the waters off the Somali coast. It also contributes to the economic and social development of Djibouti and enables China to make new and greater contributions to safeguarding peace and stability in Africa and the world.

Over the past six years, the capabilities of the support base have steadily improved. The base has provided efficient and professional support for escort fleets and Chinese peacekeeping troops deployed to South Sudan, Mali and the Democratic Republic of the Congo. The construction and growth of the support base has strongly aided the Chinese military’s escort missions in the Gulf of Aden and peacekeeping operations in Africa, while making prominent contributions to regional peace and stability and safeguarding international maritime channels.

The Chinese support base plays an important role in maintaining regional trade flows, Aboubaker Omar Hadi, chairman of the Djibouti Ports and Free Zones Authority, told People’s Daily.

The PLA support base promotes mutual trust and understanding, and conveys a message of peace and friendship.

Since its establishment, the base has held over 10 joint exercises and drills with Djiboutian and other foreign troops in Djibouti. It has also participated in more than 200 bilateral and multilateral exchange activities, and held five multinational basketball and football tournaments. This has continuously advanced bilateral and multilateral exchanges and showcased the open and confident image of the Chinese military.

Since 2019, the PLA Support Base Hospital in Djibouti has partnered with the general hospital of Djibouti’s military for paired assistance. So far, China has sent over 100 medical experts to Djibouti, assisted with 45 surgeries there and held a series of bilateral clinical skills training sessions.

The base has become an important platform for medical exchanges, said Feng Dan, a medic who has joined multiple exchange activities. “We are very proud to be doctors at the base,” Feng told People’s Daily.

Advertisement

Fran, a military doctor at the Djibouti Military Hospital of the Djiboutian Republican Guard, said that China’s long-term medical assistance is important for Djibouti and it is hoped that there will be further exchanges with the Chinese side to improve local medical capabilities.

Li Zhaohui, head of the PLA support base, noted that the base hopes to strengthen its communication with Djibouti and foreign troops in Djibouti, constantly enhance practical cooperation with them, fulfill China’s international obligations, and work together with them to cope with security threats and challenges, so as to make greater contributions to regional peace and stability.

Teenagers are the future of Djibouti’s economic and social development, as well as the hope for the continuous friendship between China and Djibouti. In order to improve the teaching conditions in local schools, the support base has established a regular education assistance mechanism with Djibouti, which conducts public welfare assistance activities.

In January this year, the support base donated computers, projectors, desks and chairs, sports equipment and stationery to three primary schools in the Balbala district of Djibouti City. It was the support base’s third round of public welfare assistance to local schools.

“The new desks, chairs, and equipment have made our school more beautiful,” said Hassan, a student at the PK12 Primary School in Djibouti City, carrying his new blue backpack with a happy smile on his face.

Minister of National Education and Vocational Training of Djibouti Moustapha Mohamed Mahamoud said that with the help of the PLA support base, the teaching environment of local schools has been improved, providing children with better conditions for growth.

“I’m grateful to Chinese doctors and nurses,” said Mohamed Ali Ahmed, a 66-year-old man from Djibouti, who had his cataract cured at the PLA support base after having had the problem for six years.

In December 2019, the support base kicked off a 25-day medical campaign in cooperation with Djibouti’s Ministry of Health, which offered free cataract surgery for over 100 local patients including Ahmed. The campaign received widespread praise from the local community.

Ten medical staff members of the support base were awarded with the Independence Day Medal signed by President Ismail Omar Guelleh of Djibouti.

Saleh Banoita Tourab, then secretary-general of the Ministry of Health in Djibouti, noted that the Chinese military doctors have brought great relief to local cataract patients, and their act of compassion will be forever remembered by the people of Djibouti.

Advertisement

In 2019, Djibouti experienced a rare heavy rainfall, which caused flooding and resulted in casualties. In response to Djibouti’s request, the PLA support base dispatched troops to provide assistance to the affected population, and thousands of people received timely help.

Idle, a resident of Djibouti, and his family and friends were severely affected by the flood. “The house of a friend of mine was almost swallowed by the flood, and we felt desperate,” he said. Fortunately, Chinese soldiers arrived and helped them with drainage and dredging. “We are grateful to the Chinese military,” Idle said.

Since its establishment, the support base has been committed to assisting in the local economic and social development of Djibouti through various initiatives such as public welfare education, medical services, and disaster relief. These practical actions have earned widespread praise from the government and people of Djibouti.

“When I first arrived in Djibouti in 2018, there were few locals who could speak Chinese,” said Zhang Daqian, a PLA officer who has been stationed at the base for five years. He told People’s Daily that whenever the soldiers go out on missions nowadays, local people would warmly greet them in Chinese and give thumbs-up to them.

“This change is a testament to the unwavering dedication of Chinese soldiers who have been serving the local community. It inspires us and motivates us to continue our efforts,” Zhang said.

 

View original content:https://www.prnewswire.co.uk/news-releases/a-report-from-peoples-daily–pla-support-base-in-djibouti-pursues-peace-cooperation-friendship-301924970.html

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Statement of Ad Hoc Lebanon Bondholder Group

Published

on

statement-of-ad-hoc-lebanon-bondholder-group

LONDON and NEW YORK, Jan. 15, 2025 /PRNewswire/ — In March 2020, several of the largest institutional holders of sovereign bonds issued by Lebanon formed a group (the “Ad Hoc Group”) in response to the deteriorating financial and economic situation in the country and the government’s decision to default on its international bonds.  The Ad Hoc Group’s stated objective from the outset has been to find a sustainable and equitable solution to Lebanon’s severe debt challenges. The Ad Hoc Group is supported by White & Case LLP as legal advisor. 

The intervening years have witnessed a further decline of Lebanon’s political, economic and security situation, which has prevented any meaningful engagement with the Lebanese authorities.  Despite the lack of progress to date, the Ad Hoc Group continues to provide a forum for coordination and communication among international bondholders, and remains prepared to engage constructively with the Lebanese authorities and other domestic and international stakeholders.

In this regard, the Ad Hoc Group is encouraged by the recent election of Joseph Aoun as President of Lebanon and nomination of Nawaf Salam as prime minister, and looks forward to the formation of a new government that will have the mandate to address the many challenges facing the country. 

The Ad Hoc Group also takes note of last week’s statement of the Council of Ministers of Lebanon relating to the proposed suspension of Eurobond prescription periods until 9 March 2028, and confirms its willingness to discuss the implementation of the proposed suspension with the authorities and, at the appropriate time, to engage more broadly to find a resolution to the longstanding debt default.

Holders of Lebanon’s international bonds who wish to learn more about the Ad Hoc Group and its objectives, or discuss recent developments, may contact White & Case LLP by emailing WCLebanonBondholderGroup@whitecase.com.

View original content:https://www.prnewswire.co.uk/news-releases/statement-of-ad-hoc-lebanon-bondholder-group-302351961.html

Continue Reading

Fintech PR

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Published

on

cutting-edge-cancer-therapies-lead-the-way-into-a-transformative-year

Issued on behalf of Oncolytics Biotech Inc.

USA News Group News Commentary

VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ — As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds great promise for precision medicine and immunotherapy. Amid growing expectations for an active year for biotech stocks in 2025, developers of new cancer therapies are already releasing important developments, with recent news coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Adaptive Biotechnologies Corporation (NASDAQ: ADPT), NeoGenomics, Inc. (NASDAQ: NEO), Elevation Oncology, Inc. (NASDAQ: ELEV), and ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC).

The article continued: Statista analysts project that the oncology drugs market will generate an estimated revenue of $208.9 billion in 2025. Meanwhile, Global Market Insights reports that the global oncology market, valued at approximately $320.3 billion in 2024, is expected to grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2034, reaching $866.1 billion.

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany’s medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without atezolizumab (Tecentriq®) in newly diagnosed pancreatic ductal adenocarcinoma (PDAC) patients.

Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment. Early safety data will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year.

“Pelareorep has the potential to meaningfully improve outcomes for patients with metastatic pancreatic cancer,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer for Oncolytics Biotech. “Encouraging tumor response rates observed in an earlier cohort of the GOBLET study underscore pelareorep’s promise in this disease. GOBLET Cohort 5 extends our evaluation by testing pelareorep with a different chemotherapy regimen, mFOLFIRINOX, which broadens the range of pancreatic cancer patients who may benefit from this innovative therapy. Positive results from this cohort may ultimately enable pelareorep to benefit the large majority of metastatic pancreatic patients for whom improved treatment options are badly needed.”

The Phase 1/2 GOBLET study is testing pelareorep, an oncolytic reovirus, in combination with other treatments for advanced gastrointestinal cancers, including pancreatic, colorectal, and anal cancers. Conducted at 17 centers in Germany, the study aims to evaluate response rates, safety, and biomarkers across multiple treatment arms, with promising cohorts advancing to further testing.

AIO is a non-profit organization that evolved from the medical oncology working group within the German Cancer Society (DKG). Dedicated to advancing science and research in medical oncology, AIO has grown into a prominent sponsor and study management company. Over the years, it has established a strong reputation both within Germany and on the international stage for its contributions to oncology research and study development.

Advertisement

Oncolytics Biotech’s work represents a significant step forward in the fight against metastatic pancreatic cancer, addressing a critical need for more effective treatment options in this aggressive disease. By leveraging the innovative potential of pelareorep in combination with established therapies, the company is paving the way for breakthroughs that could transform outcomes for patients and unlock value for investors.

CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

In other recent industry developments and happenings in the market include:

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, recently announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

Adaptive’s clonoSEQ® is the first and only FDA-cleared test for detecting minimal residual disease (MRD) in lymphoid cancers, while NeoGenomics’ COMPASS® and CHART® offer comprehensive and personalized testing for complex blood cancers. By combining clonoSEQ with these advanced services, oncologists can develop tailored treatment plans, assess patient risk more accurately, and gain real-time insights into disease progression, enhancing care for blood cancer patients.

“As a leader in oncology testing with an extensive menu of precision oncology offerings, NeoGenomics is a natural partner for us,” said Chad Robins, CEO and Co-Founder of Adaptive Biotechnologies. “We are proud of this collaboration, which expands access to the valuable insights that clonoSEQ MRD results offer, ultimately helping more providers and patients benefit from knowing their MRD status.”

Under a new agreement, clinicians using NeoGenomics’ COMPASS diagnostic tool for blood cancers like multiple myeloma, B-ALL, CLL, and DLBCL can now include Adaptive Biotechnologies‘ clonoSEQ Clonality (ID) test at diagnosis to identify patient-specific DNA sequences for ongoing MRD (minimal residual disease) tracking. This integration allows seamless monitoring of disease burden throughout treatment using CHART, giving patients access to clonoSEQ insights and increasing eligibility for clinical trials that rely on MRD testing to guide therapy decisions. All clonoSEQ testing will be conducted at Adaptive’s specialized laboratory, ensuring accurate and consistent results. 

Adaptive and NeoGenomics are preparing to implement the infrastructure for their partnership, with cross-promotional efforts expected to launch later this year, though financial terms remain undisclosed.

iBio, Inc. (NYSE-American: IBIO) an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., recently announced they’ve developed a breakthrough antibody targeting Activin E, a key protein linked to cardiometabolic disorders and obesity. This achievement demonstrates the strength of iBio’s platform in tackling challenging targets and advancing innovative therapies, with plans for rapid testing of this and other candidates in advanced disease models.

“Developing a functional antibody against Activin E, an achievement we believe to be an industry first, is a significant milestone for iBio,” said Martin Brenner, Ph.D., DVM, iCEO and Chief Scientific Officer of iBio. “This breakthrough strengthens our efforts to expand our therapeutics pipeline for the treatment of cardiometabolic disorders and obesity with innovative next-generation solutions.”

Advertisement

Elevation Oncology, Inc. (NASDAQ: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, recently announced program updates and upcoming milestones.

The company is advancing its pipeline with EO-3021, a potentially best-in-class antibody drug conjugate targeting Claudin 18.2 in advanced gastric/GEJ cancer, showing promising early results with a 42.8% overall response rate and a differentiated safety profile. The ongoing Phase 1 trial includes monotherapy and combination studies, with additional data expected in 2025 and 2026, while EO-1022, a HER3-targeting ADC for solid tumors, is progressing toward preclinical data release in 2025 and an IND filing in 2026.

“We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care,” said Joseph Ferra, President and CEO of Elevation Oncology. “As we enter 2025, we are honing our focus, leveraging the competitive anti-tumor activity and differentiated safety profile of EO-3021 to explore combination approaches in the first- and second-line settings.”

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, recently provided early Phase 1b combination data for ORIC-944, operational highlights for 2024, and anticipated upcoming milestones.

ORIC-944, a potent PRC2 inhibitor, has shown strong potential in treating metastatic castration-resistant prostate cancer (mCRPC), with deep and durable PSA responses and a favorable safety profile in early Phase 1b combination trials with apalutamide and darolutamide. Alongside advancements in ORIC-114 for NSCLC, ORIC’s 2024 milestones include promising clinical data, strategic collaborations with Johnson & Johnson and Bayer, and a robust cash position expected to support operations into late 2026, positioning the company for continued progress in oncology drug development.

“We made strong progress on multiple fronts in 2024, most notably with the initiation of multiple cohorts for ORIC-114 in NSCLC and ORIC-944 in mCRPC,” said Jacob M. Chacko, M.D., President and CEO of Oric. “We also forged three strategic collaborations with leading pharma partners, strengthened our leadership team to expand functional capabilities, and completed a $125 million PIPE financing, extending our cash runway into late 2026. These accomplishments position us well for 2025 and beyond, with seven anticipated data readouts over the next 18 months as we advance toward potentially initiating registrational studies for ORIC-114 in the second half of 2025 and for ORIC-944 in early 2026.”

Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/cutting-edge-cancer-therapies-lead-the-way-into-a-transformative-year-302351959.html

Continue Reading

Fintech PR

TIC Holding Schweiz / Winterberg acquire Metron Measurement SA

Published

on

tic-holding-schweiz-/-winterberg-acquire-metron-measurement-sa

TIC Holding Schweiz AG, a Buy, Build and Technologize platform funded by Winterberg Investment X and managed by Winterberg Advisory GmbH, has acquired Metron Measurement SA based in Quartino, Switzerland

BAAR, Switzerland, Jan. 15, 2025 /PRNewswire/ — TIC Holding Schweiz has successfully completed the acquisition of Metron Measurement SA, an SCS-accredited laboratory specialized in calibrating measurement equipment in the field of Length, Force, Torque, Humidity, Pressure and Electrical quantities. Metron further offers active administration and handling of all the equipment of their customers and can even perform its services onsite.

 

 

TIC (Testing, Inspection, and Certification) services have been a focus for private equity groups for decades, particularly in Europe, driven by the sector’s non-cyclical nature and high levels of recurring revenues. Winterberg has explored this sector in Switzerland for more than three years before making its first acquisition and is currently pursuing further live transactions.

Lorenzo Tencati, Board Member at TIC Holding Schweiz and Partner in Winterberg, states: “After being in the M&A market in TIC in Switzerland for a long time, we have finally found the nucleus of our new platform. Metron has strong processes, and impressive growth and a highly motivated team to deliver its services at the highest standards, to the utmost satisfaction of its customers. We are also very happy that Alessandro Capone stays with us as CEO of Metron with a significant shareholding in TIC Holding Schweiz. Together with my partner Fabian Kroeher and the Winterberg team we are all up for an exciting journey to build a Swiss market leader in the next 5 to 7 years.”

Alessandro Capone, CEO of Metron Measurement, adds: “From the first meeting, we were convinced that Winterberg will be the right partner to take Metron to the next level. We have been growing our services and team every year and really look forward to now be able to strategically invest and grow by acquisition in addition. We are also extremely grateful to our first investor Brütsch Rüegger Tools and especially to its CEO Martin Wirth for their support and trust in us during the last 10 years of activity, since 2015. We want to ensure that our collaboration in the market remains at its current level and that we continue to best meet our customers’ needs.”

Martin Wirth, CEO of Brütsch Rüegger Tools, affirms: “We are pleased to transfer our stake in Metron to an investor poised to further develop the company strategically and to expand the group into new sectors beyond our current scope. We are confident they will successfully drive Metron’s continued growth and build on its strong momentum. Metron is and remains our reliable exclusive partner for testing and calibration services – a long-standing partnership that will continue. We will keep providing our customers with calibration services and process-integrated calibration solutions based on Metron’s comprehensive portfolio of expertise and solutions.”

About TIC Holding Schweiz AG

Advertisement

TIC Holding Schweiz aims at becoming one of Switzerland’s leading customer-centric groups with a strong commitment to quality, excellence and diversity. The holding is actively seeking to acquire small and medium enterprises in accredited Testing, Inspection and Certification Services, preferably in succession situations. By fostering an entrepreneurial culture and benefiting from latest technologies in all corporate functions, it aspires to generate above-market growth and returns. TIC Holding Schweiz is based in Baar, Switzerland and its first group company Metron Measurement SA is located in Quartino, Switzerland.

About Winterberg Advisory GmbH and Winterberg Group AG

Based in Gruenwald, Germany, Winterberg Advisory GmbH manages private equity investment funds, mainly concentrating on small- and mid-cap successions, creating Buy, Build and Technologize platforms such as TIC Holding Schweiz AG and Healthcare Holding Schweiz AG. Winterberg Group AG, located in Zug, Switzerland, is an independent family office that invests in private equity, along with selective ventures in real estate and other asset classes.

Note to Editors: Please credit Winterberg Group for all references to provided quotes and information.

For further information about TIC Holding Schweiz AG, please visit www.tic-holding.ch.

For further information about Metron Measurement SA, please visit www.metron-labo.ch.

For further information about Winterberg Advisory GmbH and Winterberg Group AG, please visit www.winterberg.group. Winterberg’s Swiss healthcare platform Healthcare Holding Schweiz AG can be found under www.healthcare-holding.ch

This press release is prepared and distributed by Winterberg Advisory GmbH on behalf of TIC Holding Schweiz AG.

Photo: https://mma.prnewswire.com/media/2598759/TIC_Holding_Schweiz_AG.jpg

For media inquiries, please contact:
Kaja Funke 
presse@tic-holding.ch
+4915118859825

Advertisement

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tic-holding-schweiz–winterberg-acquire-metron-measurement-sa-302351890.html

Continue Reading

Trending